Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: S01

Beovu(brolucizumab)

Wet Macular Degeneration

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 13/02/2020

INN: brolucizumab

Indication

Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Beovu — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.